Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca/MedImmune Synergies An Advantage In Immune-Mediated Cancer Therapies

Executive Summary

AstraZeneca’s ability to combine its small molecules with MedImmune’s biologics gives the company an edge in the burgeoning field of immune-mediated cancer therapies, MedImmune’s oncology iMed chief said in Washington, D.C. April 7 at the AACR annual meeting.

You may also be interested in...

Cancer Checkpoint Roundup: Big Pharmas Advance Ahead of ASCO

During first-quarter earnings calls and ahead of the upcoming American Society of Clinical Oncology meeting, big pharma execs stressed the importance of developing immunotherapies in a range of cancers and highlighted the progress made so far.

Follow The Leader: Bristol Aims To Build On Head Start In Cancer Immunotherapy

The potential for cancer immunotherapy was the clear takeaway from ASCO 2013. With a lead on the competition, a portfolio with a variety of intriguing mechanisms and many combination trials ongoing, Bristol looks to take immuno-oncology development to the next level.

AstraZeneca Oncology Focused On Combinations, But Differentiation Will Be Key

AstraZeneca is in the midst of a concerted push in oncology, but many of its top contenders are in crowded classes. The firm sees its future in the possibilities of combinations with immunotherapies.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts